✉ Email this page to a colleague
« Back to Dashboard
Lamotrigine is a drug marketed by Actavis Elizabeth, Amneal Pharms, Anchen Pharms, Atlantide, Dr Reddys Labs Ltd, Par Pharm, Rubicon, Torrent, Yiling, Zydus Pharms, Alembic Pharms Ltd, Aurobindo Pharma, Glenmark Pharms Ltd, Jubilant Generics, Mylan, Sandoz, Taro, Teva, Watson Labs, Zydus Pharms Usa Inc, Ajanta Pharma Ltd, Amring Pharms, Impax Labs Inc, Sciegen Pharms Inc, Actavis Totowa, Alkem Labs Ltd, Cipla, Glenmark Generics, Granules, Hikma Pharms, Jubilant Cadista, Lupin Ltd, Mylan Labs Ltd, Rising, Roxane, Taro Pharm Inds, Torrent Pharms, Unichem Labs Ltd, Zennova, and Zydus Pharms Usa. and is included in forty-nine NDAs.
The generic ingredient in LAMOTRIGINE is lamotrigine. There are thirty-two drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the lamotrigine profile page.
A generic version of LAMOTRIGINE was approved as lamotrigine by DR REDDYS LABS LTD on January 22nd, 2009.
Summary for LAMOTRIGINE
|Finished Product Suppliers / Packagers:||48|
|Raw Ingredient (Bulk) Api Vendors:||135|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price information for LAMOTRIGINE|
|Drug Sales Revenues:||Drug sales revenues for LAMOTRIGINE|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for LAMOTRIGINE|
|What excipients (inactive ingredients) are in LAMOTRIGINE?||LAMOTRIGINE excipients list|
|DailyMed Link:||LAMOTRIGINE at DailyMed|
Recent Clinical Trials for LAMOTRIGINE
Identify potential brand extensions & 505(b)(2) entrants
|Brown University||Phase 2|
|National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Phase 2|
|Postgraduate Institute of Dental Sciences Rohtak||Phase 4|
Pharmacology for LAMOTRIGINE
|Drug Class||Anti-epileptic Agent |
|Mechanism of Action|| Dihydrofolate Reductase Inhibitors |
Organic Cation Transporter 2 Inhibitors
|Physiological Effect|| Decreased Central Nervous System Disorganized Electrical Activity |